Inês Martins, PhD, managing science editor —

An exercise intervention program can improve bone health in children with Prader-Willi syndrome (PWS) and potentially lower the risk of osteoporosis later in life, a six-month clinical trial shows. While improvements were reported in only some bones, and not in markers of bone turnover, researchers believe that longer intervention…

Children with Prader-Willi syndrome (PWS) whose disease is caused by a deletion in part of chromosome 15 may be more prone to obesity than others with non-deletion disease causes, a study suggests. Different gene expression in the brain likely explains the variability in patients from each group, researchers…

Children with Prader-Willi syndrome (PWS) have abnormally high blood levels of certain inflammatory molecules, which is significantly associated with behavioral traits and symptoms of the condition, a recent study has found. The study, “A pro‑infammatory phenotype is associated with behavioural traits in children with Prader–Willi…

Vitamin D levels are lower among adults with Prader-Willi syndrome (PWS) that in other obese individuals, mainly because PWS patients tend to consume less vitamin D through their diet, a study suggests. The study, “The Sun’s Vitamin in Adult Patients Affected by Prader–Willi Syndrome,” was…

Central adrenal insufficiency, a deficiency in cortisol levels due to problems in the pituitary or hypothalamus, is rare in people with Prader-Willi syndrome (PWS), affecting 1.2% of patients, a study shows. Researchers, therefore, do not recommend routinely prescribing medications for central adrenal insufficiency to PWS patients — as…

This May, the Foundation for Prader-Willi Research (FPWR) is mobilizing people around the world affected by Prader-Willi syndrome (PWS) to raise awareness about the disease and host fundraising activities to advance disease research. This year’s PWS Awareness Month came to be thanks to the efforts of Republican…

Millendo Therapeutics‘ treatment candidate livoletide failed to significantly reduce hunger and improve food-related behaviors in people with Prader-Willi syndrome (PWS) who are taking part in the pivotal ZEPHYR Phase 2b/3 clinical trial. Also, the treatment did not improve other measures, such as body fat, waist circumference,…